This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Identifying Factors Underlying the Discontinuation of Triptans

This study has been completed.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Todd J. Schwedt, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00890357
First received: April 27, 2009
Last updated: March 27, 2013
Last verified: March 2013
  Purpose
The objective of this study is to identify reasons migraine patients stop using triptan medications for abortive headache treatment. It is hypothesized that inadequate education of the patient at the time of prescribing the triptan is positively associated with triptan discontinuation.

Condition
Migraine Medication Adherence

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Identifying Factors Underlying the Discontinuation of Triptans

Resource links provided by NLM:


Further study details as provided by Todd J. Schwedt, Mayo Clinic:

Enrollment: 292
Study Start Date: August 2009
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Triptan User
Triptan Discontinued

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult Specialty Headache Clinics
Criteria

Triptan User Inclusion Criteria:

  • Episodic Migraine or Chronic Migraine
  • Have used a triptan medication in the prior 3 months
  • Have used triptan medications for at least 1 year

Triptan Discontinuation Inclusion Criteria:

  • Episodic Migraine or Chronic Migraine
  • Used any triptan medication in the last 2 years
  • Have not used a triptan medication in the last 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00890357

Locations
United States, Florida
University of South Florida College of Medicine
Tampa, Florida, United States, 33612
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
Mayo Clinic
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Todd Schwedt, MD Mayo Clinic
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Todd J. Schwedt, PI, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00890357     History of Changes
Other Study ID Numbers: 09-0111
Study First Received: April 27, 2009
Last Updated: March 27, 2013

Additional relevant MeSH terms:
Sumatriptan
Vasoconstrictor Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 21, 2017